AbCellera Q1 2026 Results — Positive Phase 1 Data for ABCL635
Stocks · · 1 min read · x.com ↗
AbCellera Q1 2026 Results — Positive Phase 1 Data for ABCL635
$ABCL (AbCellera Biologics Inc.) reports Q1 2026 business results alongside positive interim Phase 1 clinical data for ABCL635.
Key points from the announcement:
- Q1 2026 business results released
- Positive interim Phase 1 clinical data for ABCL635 (their clinical-stage therapeutic candidate)
- Investor press release was posted but the original page is now returning 404 — may need to check SEC filings for full details
Note: The investor.press release URL (investors.abcellera.com) returned a 404 error. Full Q1 financials and ABCL635 clinical data details should be available via SEC filings (10-Q) once filed.
Source: X post by @abcellerabio Captured: 2026-05-11T20:39:47Z Note: Original press release page returned 404 at time of scraping. Check SEC filings for full financials.